Key result
Ticagrelor, ruciromab, and PGE1, but not aspirin, curb platelet-dependent thrombin generation and fibrin formation.
Why the study?
To investigate the effects of antiplatelet drugs on platelet impact in fibrin formation, thrombin generation, and phosphatidylserine exposure.
Do antiplatelet drugs (ASA, ticagrelor, ruciromab, PGE1) reduce platelet-dependent coagulation reactions and phosphatidylserine exposure in human platelets?
Do antiplatelet drugs (ASA, ticagrelor, ruciromab, PGE1) reduce platelet-dependent coagulation reactions and phosphatidylserine exposure in human platelets?
Answers are grounded in this paper and cite their sources.
Ticagrelor, ruciromab, and PGE1, but not aspirin alone, suppress platelet-dependent coagulation activity and phosphatidylserine exposure both in vitro and in patients with ACS.
Activated platelets are involved in blood coagulation by exposing phosphatidylserine (PS), which serves as a substrate for assembling coagulation complexes. Platelets accelerate fibrin formation and thrombin generation, two final reactions of the coagulation cascade. We investigated the effects of antiplatelet drugs on platelet impact in these reactions and platelet ability to expose PS. Washed human platelets were incubated with acetylsalicylic acid (ASA), ticagrelor, ASA in combination with ticagrelor, ruciromab (glycoprotein IIb-IIIa antagonist), or prostaglandin E1 (PGE1). Platelets were not activated or activated by collagen and sedimented in multiwell plates, and plasma was added after supernatant removal. Fibrin formation (clotting) was monitored in a recalcification assay by light absorbance and thrombin generation in a fluorogenic test. PS exposure was assessed by annexin V staining using flow cytometry. Ticagrelor (alone and in combination with ASA), ruciromab, and PGE1, but not ASA, prolonged the lag phase and decreased the maximum rate of plasma clotting and decreased the peak and maximum rate of thrombin generation. Inhibition was observed when platelets were not treated with exogenous agonists (activation by endogenous thrombin) and pretreated with collagen. Ticagrelor (alone and in combination with ASA), ruciromab, and PGE1, but not ASA, decreased PS exposure on washed platelets activated by thrombin and by thrombin + collagen. PS exposure on activated platelets in whole blood was lower in patients with acute coronary syndrome receiving ticagrelor + ASA in comparison with donors free of medications. These results indicate that antiplatelet drugs are able to suppress platelet coagulation activity not only in vitro but also after administration to patients.
No takes yet. Share an insight, caveat, or question.
Muravlev et al. (2023) studied Acute coronary syndrome and healthy volunteers (in vitro and ex vivo platelet coagulation study). Antiplatelet drugs (acetylsalicylic acid, ticagrelor, ruciromab, prostaglandin E1) vs. Untreated control platelets / healthy volunteers free of medications was evaluated on Platelet-dependent fibrin formation, thrombin generation, and phosphatidylserine (PS) exposure. Ticagrelor, ruciromab, and PGE1, but not aspirin, reduced platelet-dependent fibrin formation, thrombin generation peak, and phosphatidylserine exposure.
Synapse has enriched 10 related papers. Consider them for comparative context: